219370 Coagulation Factor VIIa, Human Plasma

219370
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité

      Aperçu

      Replacement Information

      Prix & Disponibilité

      Référence DisponibilitéConditionnement Qté Prix Quantité
      219370-10UG
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Ampoule plast. 10 μg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewNative coagulation factor VIIa from human plasma prepared from human Factor VII using human Factor XIIa, which was removed after activation. In the coagulation process, after complexing with tissue factor and membrane phospholipids, Factor VIIa activates Factors IX and X to the enzymatically active Factors IXa and Xa. Provides a crossover point between the extrinsic and intrinsic pathways.
          Catalogue Number219370
          Brand Family Calbiochem®
          References
          ReferencesBroze, G.J. 1994. In Haemostasis and Thrombosis, 3rd Edition(Bloom, et al. Eds.) Churchill Livingstone, Edinburgh, p 349.
          Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al. Eds.) Pergamon Press, New York, p 1311.
          Product Information
          EC number3.4.21.21
          FormLiquid
          FormulationIn 100 mM NaCl, 20 mM Tris-HCl, pH 7.5.
          Quality LevelMQ100
          Applications
          Biological Information
          Purity≥95% by SDS-PAGE
          SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          Specific Activity≥25,000 PEU/mg protein (clotting assay). Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial use aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Coagulation Factor VIIa, Human Plasma FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Coagulation Factor VIIa, Human Plasma Certificats d'analyse

          TitreNuméro de lot
          219370

          Références bibliographiques

          Aperçu de la référence bibliographique
          Broze, G.J. 1994. In Haemostasis and Thrombosis, 3rd Edition(Bloom, et al. Eds.) Churchill Livingstone, Edinburgh, p 349.
          Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al. Eds.) Pergamon Press, New York, p 1311.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision05-June-2008 RFH
          DescriptionNative coagulation factor VIIa from human plasma prepared from human Factor VII using human Factor XIIa, which was removed after activation. Factor VIIa provides a crossover point between the extrinsic and intrinsic pathways. Prepared from human Factor VII using Human Factor XIIa.
          FormLiquid
          FormulationIn 100 mM NaCl, 20 mM Tris-HCl, pH 7.5.
          Concentration Label Please refer to vial label for lot-specific concentration
          SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          EC number3.4.21.21
          Purity≥95% by SDS-PAGE
          Specific activity≥25,000 PEU/mg protein (clotting assay). Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial use aliquot and freeze (-70°C).
          Toxicity Standard Handling
          ReferencesBroze, G.J. 1994. In Haemostasis and Thrombosis, 3rd Edition(Bloom, et al. Eds.) Churchill Livingstone, Edinburgh, p 349.
          Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al. Eds.) Pergamon Press, New York, p 1311.